Minimally invasive therapies for benign prostatic hyperplasia

Area of Science:

• Urology
• Minimally Invasive Surgery
• BPH Treatment

Background:

• Benign prostatic hyperplasia (BPH) affects a significant number of men, leading to lower urinary tract symptoms.
• Traditional treatments like transurethral resection of the prostate (TURP) have limitations.
• Minimally invasive therapies have emerged as alternatives, often using thermal energy.

Purpose of the Study:

• To review the efficacy, safety, and re-treatment rates of minimally invasive therapies for BPH.
• To compare these therapies with pharmacotherapy and TURP.
• To identify patient populations that may benefit most from these alternative treatments.

Main Methods:

• Review of studies on minimally invasive therapies for BPH.
• Analysis of data regarding long-term efficacy, safety, and re-treatment rates.
• Comparison of outcomes with established treatments like TURP.

Main Results:

• Minimally invasive therapies offer symptom relief with potentially lower morbidity and shorter hospital stays.
• Transurethral needle ablation (TUNA) and high energy transurethral microwave thermotherapy (HE-TUMT) show promise.
• Laser prostatectomy is less favored due to procedural challenges.
• These therapies are suitable for patients on anticoagulants or with contraindications to anesthesia.

Conclusions:

• Minimally invasive therapies represent a viable option between pharmacotherapy and TURP for BPH symptom management.
• Further large-scale, controlled trials are needed to establish long-term durability and confirm their place in BPH treatment algorithms.
• Long-term data is crucial to determine if these therapies can eventually replace TURP.